| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥2907.7B | ¥3016.0B | -3.6% |
| Operating Income | ¥182.0B | ¥118.2B | +54.0% |
| Ordinary Income | ¥137.0B | ¥43.3B | +216.4% |
| Net Income | ¥20.6B | ¥23.2B | -11.3% |
| ROE | 0.7% | 0.8% | - |
FY2025 Q3 cumulative results: Revenue ¥290.8B (YoY -3.6%), Operating Income ¥18.2B (+54.0%), Ordinary Income ¥13.7B (+216.4%), Net Income ¥2.1B (-11.3%). Despite revenue contraction, operating income improved significantly driven by temporary factors including US DPE plant suspension effects (+¥4.2B) and disposal gains from Ofuna factory site sale (+¥8.2B). However, extraordinary losses related to DPE closure (¥13.5B) substantially impacted net income. Operating margin improved to 6.3% from 3.9% YoY, but profitability remains constrained by high interest burden (interest expense ¥1.6B) and forex losses (¥1.2B). The company maintained its full-year guidance of ¥390.0B revenue, ¥25.0B operating income, and ¥15.0B net income, with annual dividend of ¥100 per share.
Revenue declined 3.6% YoY to ¥290.8B, primarily due to reduced volumes in Life Innovation segment (COVID-19 test kit demand normalization) and Elastomer & Infrastructure Solutions segment (cement production ended June 2025). However, Electronics & Innovative Products segment grew through expanded demand in AI-related semiconductors and power infrastructure applications, with volume effects contributing +¥4.7B.
Operating income surged 54.0% to ¥18.2B, with margin expansion from 3.9% to 6.3%. The primary driver was the US DPE plant suspension effect (+¥4.2B improvement), representing a non-recurring operational restructuring benefit. Electronics & Innovative Products contributed +¥2.8B through volume growth in spherical alumina/silica for AI applications. Polymer Solutions added +¥0.9B from price optimization in food packaging sheets. These gains were partially offset by Life Innovation (-¥1.0B) due to increased depreciation from capacity expansion.
Ordinary income increased 216.4% to ¥13.7B, significantly outpacing operating income growth. Non-operating items included interest expense of ¥1.6B and forex losses of ¥1.2B, though forex effects improved +¥1.2B YoY as USD/JPY averaged 148.5 yen versus prior year. The interest burden coefficient of 0.452 indicates approximately 55% of operating profit is consumed by financing costs and other non-operating items, representing a structural profitability constraint.
Net income of ¥2.1B declined 11.3% despite ordinary income gains, due to substantial extraordinary losses. Special losses totaled ¥14.2B, primarily DPE-related charges (¥13.5B) including raw material write-downs and extraction work costs. These were partially offset by special gains of ¥8.7B, mainly from Ofuna factory site disposal (+¥8.2B). The effective tax rate reached 75.0%, elevated due to extraordinary loss impacts. Excluding one-time items (special gains ¥8.7B and losses ¥14.2B), recurring net income would approximate ¥7.6B, indicating core profitability remains modest relative to operating income.
Pattern: Revenue down, profit up (driven by operational restructuring and asset disposal gains, with significant non-recurring item dependency).
Electronics & Innovative Products: Revenue ¥75.9B, Operating Income ¥9.7B (margin 12.8%). This segment represents the core growth driver, with operating income of ¥9.7B increasing ¥2.8B YoY. Volume effects contributed +¥4.7B from robust demand in AI-related semiconductor materials (spherical alumina, spherical silica) and power infrastructure applications. The segment demonstrates the highest margin among all segments and accounted for approximately 53% of consolidated operating income. Depreciation increased ¥1.3B due to capacity expansion investments, partially offsetting volume gains. This segment's performance confirms its position as the strategic core business driving profitability improvement.
Life Innovation: Operating Income ¥6.6B, declining ¥1.0B YoY. While influenza vaccine volumes remained stable, COVID-19 antigen rapid test kit volumes declined significantly due to normalization of pandemic-related demand. Clinical diagnostic reagent sales also softened in overseas markets. Depreciation increased ¥0.8B due to capacity expansion for diagnostic kits and clinical reagents, compressing margins. The segment maintained profitability but faces headwinds from pandemic demand normalization.
Elastomer & Infrastructure Solutions: Operating Loss ¥2.3B, improving ¥3.4B YoY. The dramatic improvement was driven entirely by DPE plant suspension effects (+¥4.2B), a non-recurring restructuring benefit. Chloroprene rubber volumes remained flat YoY, but sales shifted from DPE products to Aomi plant products following the US plant closure. Special admixture demand declined due to construction delays, and cement production ended in June 2025. Inventory valuation impacts contributed -¥1.0B. This segment remains loss-making but shows structural improvement through operational restructuring.
Polymer Solutions: Operating Income ¥2.0B, improving ¥0.9B YoY. Price optimization (+¥1.2B) in food packaging sheets and containers drove the improvement, successfully passing through cost increases to customers. MS resin volumes declined due to competition from Chinese products, while styrene-based resins (AS, ABS, transparent resins) remained flat. Toyokalon showed gradual recovery. Variable costs improved from lower raw material and fuel prices. This segment demonstrates pricing power in differentiated products.
The Electronics & Innovative Products segment is clearly the core business by profitability contribution and growth trajectory, accounting for over half of consolidated operating income and driving overall performance improvement through AI-related semiconductor material demand.
Profitability: ROE 1.8% (calculated from net margin 1.9%, asset turnover 0.444, financial leverage 2.1x), Operating Margin 6.3% (prior year 3.9%). ROE remains significantly below the manufacturing industry median of 5.0%, indicating weak return on capital. Operating margin improved but remains below industry median of 8.3%, reflecting structural cost challenges and business mix. EBIT margin of 6.3% with tax burden coefficient of 0.673 indicates high effective tax burden. Net profit margin of 1.9% is substantially below industry median of 6.3%, highlighting profitability constraints from interest burden and extraordinary items.
Efficiency: Total Asset Turnover 0.444x (industry median 0.58x), indicating below-average asset utilization. Cash Conversion Cycle reached 228 days (DSO 115 days, DIO 194 days), dramatically exceeding industry median working capital turnover of 108 days. Inventory turnover of 194 days is nearly double the industry median of 109 days, signaling significant inventory efficiency concerns. Receivables turnover of 115 days also exceeds industry median of 83 days, indicating collection challenges.
Financial Health: Equity Ratio 47.7% (prior 47.0%), below industry median of 63.8%. Current Ratio 1.30x (industry median 2.84x) indicates constrained short-term liquidity. Quick Ratio 0.895x falls short of the 1.0x safety threshold. Interest-bearing debt ¥168.1B with Debt/Capital ratio of 35.0%. Financial leverage of 2.1x exceeds industry median of 1.53x, indicating higher leverage. The interest burden coefficient of 0.452 reveals approximately 55% of operating profit is consumed by interest and non-operating costs, representing a material structural constraint on profitability.
Investment: Construction in Progress (CIP) ratio of 21.0% indicates substantial ongoing capital investments, primarily for Electronics & Innovative Products capacity expansion. Annual CapEx guidance of ¥57.0B (revised from ¥60.0B) against depreciation of ¥29.0B yields a CapEx/D&A ratio of approximately 1.97x, well above industry median of 1.44x, confirming aggressive growth investment phase particularly in strategic semiconductor materials business.
Operating CF: Not disclosed in XBRL data for Q3 cumulative period, limiting assessment of cash generation quality. However, quality alerts indicate OCF/Net Income ratio concerns, suggesting earnings may not be fully converting to cash. The extended Cash Conversion Cycle of 228 days (DSO 115 days + DIO 194 days - DPO not disclosed) implies substantial working capital consumption, likely constraining operating cash generation despite improved operating income.
Investing CF: Specific Q3 investing cash flow not disclosed. Full-year CapEx guidance of ¥57.0B (revised from ¥60.0B, primarily due to timing shift in acetylene black Thailand plant investment) indicates substantial capital deployment. Construction in Progress balance of ¥67.8B (21.0% of fixed assets) confirms significant ongoing investment commitments. Asset disposal proceeds include Ofuna factory site sale generating ¥8.2B special gain, representing one-time cash inflow.
Financing CF: Long-term borrowings increased ¥37.0B (+46.3%) while short-term borrowings decreased ¥23.6B (-31.7%), indicating debt restructuring from short-term to long-term maturities. This refinancing improves near-term liquidity but increases cumulative interest burden over time. Dividend payments planned at ¥100 per share (total payout ratio 57% on full-year guidance basis) represent significant cash outflow.
FCF: Cannot be calculated from available data due to missing operating and investing cash flow figures. However, structural indicators suggest FCF generation is constrained: high CapEx/D&A ratio of 1.97x, working capital deterioration (CCC 228 days), and elevated interest payments (¥1.6B in Q3 cumulative) all consume cash. The combination of growth investment needs (¥57.0B annual CapEx) and dividend commitments (¥100 per share) likely results in tight or negative FCF.
Cash generation: Needs Monitoring. Operating cash flow quality cannot be confirmed, working capital efficiency has deteriorated significantly, and substantial CapEx and dividend obligations create competing cash demands. The debt refinancing to extend maturities addresses near-term liquidity but does not resolve underlying cash generation concerns.
Ordinary vs Net Income: A material gap exists between ordinary income of ¥13.7B and net income of ¥2.1B, driven by net extraordinary losses of ¥5.5B (special losses ¥14.2B minus special gains ¥8.7B). Special losses of ¥14.2B primarily consist of DPE-related charges (¥13.5B) including raw material write-downs within equipment and extraction/cleaning work costs. These are non-recurring items associated with the US chloroprene plant closure and represent one-time restructuring costs. Special gains of ¥8.7B are dominated by Ofuna factory site disposal gains (¥8.2B), also a non-recurring item from asset monetization. Management has indicated Q4 will see additional extraordinary losses from DPE extraction/cleaning work, to be offset by policy-holding stock disposal gains.
The magnitude of extraordinary items (net ¥5.5B loss) relative to net income (¥2.1B) indicates approximately 262% of reported net income is impacted by one-time items. Excluding these items, recurring net income would approximate ¥7.6B (ordinary income ¥13.7B minus estimated recurring tax), more representative of ongoing earning power but still modest relative to operating income due to high interest burden.
Non-operating income composition: Non-operating expenses include interest expense of ¥1.6B and forex losses of ¥1.2B. While forex impacts can vary period-to-period, the ¥1.6B interest burden represents approximately 8.8% of operating income, indicating a structural drag on profitability. Non-operating income also reflects dividend income and other items that partially offset these costs, but the net non-operating result compressed ordinary income to 75% of operating income levels.
Accruals quality: Operating CF data unavailable limits direct accruals assessment, but working capital deterioration signals concerns. DSO extended to 115 days and DIO to 194 days (CCC 228 days total) indicate cash is being tied up in receivables and inventory at accelerating rates. Inventory valuation charges of ¥1.0B in Elastomer segment and DPE raw material write-downs suggest prior period inventory may have been overstated. These factors collectively flag earnings quality risks where reported profits may not be fully backed by cash generation.
Overall earnings quality assessment: Moderate to low. Reported net income is heavily distorted by non-recurring extraordinary items (both gains and losses). Recurring profitability, while improved at the operating level, is materially constrained by structural interest burden (45% of operating income consumed by non-operating costs). Working capital deterioration and limited operating cash flow visibility raise concerns about cash conversion quality. Investors should focus on recurring operating income adjusted for restructuring effects (DPE +¥4.2B) to assess sustainable earning power, which remains modest relative to revenue base.
Full-year guidance maintained: Revenue ¥390.0B (YoY -2.6%), Operating Income ¥25.0B (+73.4%), Ordinary Income ¥19.0B (+248.8%), Net Income ¥15.0B (+2,034.5%). Annual dividend of ¥100 per share confirmed (¥50 interim, ¥50 year-end), representing total payout ratio of 57% on full-year earnings guidance.
Progress rate vs. full-year guidance (Q3 cumulative as % of annual target): Revenue 74.6%, Operating Income 72.8%, Ordinary Income 72.1%, Net Income 13.7%. Standard benchmarks for Q3 cumulative progress are approximately 75% (assuming even quarterly distribution). Revenue and operating/ordinary income are tracking in line with guidance at 72-75% progress rates.
However, net income progress of only 13.7% represents a dramatic deviation from the standard 75% benchmark, indicating management expects substantial Q4 net income improvement. Q3 cumulative net income of ¥2.1B implies Q4 standalone net income must reach ¥12.9B to achieve ¥15.0B annual target. This expected Q4 surge reflects planned offsetting of additional DPE extraordinary losses with policy-holding stock disposal gains and other special items. The guidance structure reveals full-year net income is heavily dependent on successful execution of Q4 extraordinary gain realization.
Operating income progress of 72.8% suggests Q4 standalone operating income of approximately ¥6.8B, roughly in line with Q3's ¥6.6B quarterly run rate, supporting guidance feasibility at the operating level. The chloroprene rubber restructuring effect (DPE suspension) is expected to contribute ¥8.6B for the full year, with ¥4.2B already realized in Q3 cumulative, implying ¥4.4B additional benefit in Q4 primarily from absence of Q4 2024 DPE maintenance costs.
Key assumption updates: USD/JPY assumption for Q4 revised to 156.2 yen (Q3 actual 148.5 yen, full-year average 150.4 yen), anticipating yen depreciation. Domestic naphtha price assumption for Q4 is 64,200 yen/kiloliter (Q3 actual 65,100 yen, full-year average 65,000 yen). CapEx guidance reduced by ¥3.0B to ¥57.0B due to timing shifts in acetylene black Thailand plant investment verification. These assumption changes appear neutral to modestly supportive of guidance.
Risks to guidance: Net income target relies on successful realization of Q4 extraordinary gains (policy stock sales) to offset planned extraordinary losses (DPE extraction work). Market volatility could impact gain realization. Electronics & Innovative Products momentum depends on sustained AI-related semiconductor demand. Life Innovation faces headwinds from pandemic demand normalization. Chloroprene rubber demand recovery remains weaker than initially expected. Forex sensitivity exists with yen strengthening posing risk to export-oriented segments. Overall, operating income guidance appears achievable, but net income target carries execution risk on extraordinary items.
Dividend policy: Annual dividend of ¥100 per share (¥50 interim paid, ¥50 year-end planned) maintained. Based on full-year net income guidance of ¥15.0B and 86.17M shares, EPS is projected at ¥174.06, yielding payout ratio of 57.5%. However, based on Q3 cumulative actual net income of ¥2.1B annualized, the dividend coverage is constrained, with Q3 results implying a calculated payout ratio of 160% on trailing earnings.
Management has articulated a new shareholder return policy targeting total return ratio of 50% (cumulative over the 8-year management plan period) with emphasis on maintaining or increasing per-share dividend amount. This represents a shift toward stable absolute dividend levels rather than strict payout ratio targeting. The ¥100 per share level is positioned as the baseline for maintenance/growth.
Share buybacks: No share repurchase program disclosed for the current period. Total return ratio of 57% cited in PDF materials equals payout ratio, indicating no buyback activity in current guidance. The 50% total return target is framed as a multi-year cumulative goal rather than annual commitment.
Sustainability assessment: Dividend sustainability is questionable based on Q3 results. The ¥100 per share payout requires full achievement of net income guidance (¥15.0B), which is heavily dependent on Q4 extraordinary gain realization (policy stock sales). If extraordinary gains fall short, recurring earnings may be insufficient to support the dividend without drawing on cash reserves. Operating cash flow disclosure is unavailable, limiting assessment of cash dividend coverage. Given the high calculated payout ratio of 160% on Q3 trailing earnings, weak cash conversion (CCC 228 days), and dependence on asset sales for net income, dividend sustainability warrants monitoring. The commitment to maintain per-share dividend suggests management prioritizes distribution stability, but this may not be sustainable if operating cash generation does not improve.
Free cash flow after dividend: Cannot be calculated due to missing operating and investing cash flow data. However, structural indicators (high CapEx ¥57.0B, working capital consumption, interest burden ¥1.6B+) suggest FCF generation is tight, making the ¥8.6B+ annual dividend commitment (¥100 × 86.17M shares) potentially reliant on asset monetization rather than organic cash generation.
Near-term:
Long-term:
【Industry Position】(Reference - Proprietary Analysis)
Profitability: ROE 1.8% substantially lags industry median of 5.0% (Q3 2025, n=98 manufacturing companies), placing the company in the bottom quartile. Operating Margin 6.3% falls below industry median of 8.3% (IQR: 4.8%-12.6%), though represents improvement from prior year 3.9%. Net Profit Margin 1.9% significantly underperforms industry median of 6.3% (IQR: 3.2%-9.0%), reflecting structural constraints from interest burden and extraordinary items. Return on Assets 0.8% (calculated) trails industry median of 3.3%, indicating weak overall asset productivity. The company's profitability metrics consistently rank below industry medians across all measures.
Efficiency: Asset Turnover 0.444x materially lags industry median of 0.58x (IQR: 0.42-0.66), indicating below-average revenue generation per asset base. Working Capital Turnover 228 days is more than double the industry median of 108 days (IQR: 72-143 days), representing a significant efficiency disadvantage. Inventory Turnover 194 days substantially exceeds industry median of 109 days (IQR: 50-155 days), highlighting excess inventory relative to sales. Receivables Turnover 115 days also exceeds industry median of 83 days (IQR: 68-115 days). The company ranks in the bottom quartile for working capital efficiency across all metrics.
Financial Health: Equity Ratio 47.7% falls well below industry median of 63.8% (IQR: 49.5%-74.7%), placing the company near the lower quartile with higher financial leverage. Current Ratio 1.30x is dramatically below industry median of 2.84x (IQR: 2.10x-3.81x), indicating materially weaker short-term liquidity. Financial Leverage 2.1x exceeds industry median of 1.53x (IQR: 1.31-1.85), reflecting above-average debt reliance. The company's financial health metrics indicate higher financial risk and lower liquidity buffers compared to manufacturing industry peers.
Growth: Revenue Growth -3.6% YoY trails industry median of +2.7% (IQR: -1.9% to +7.9%), placing the company in the bottom half. EPS Growth is not directly comparable due to extraordinary items distortion, but calculated EPS growth of +114.7% YoY is driven primarily by non-recurring factors and does not reflect sustainable growth trajectory. Rule of 40 score (revenue growth + operating margin = 2.7%) falls well below industry median of 11% (IQR: 5%-19%), indicating combined growth and profitability underperformance.
Investment Intensity: CapEx/D&A ratio of approximately 1.97x (¥57.0B CapEx / ¥29.0B D&A) exceeds industry median of 1.44x (IQR: 1.19-1.76, n=5), confirming the company is in an aggressive investment phase. This high investment intensity in Electronics & Innovative Products capacity expansion is appropriate given strategic positioning but creates near-term cash flow pressure.
Overall Industry Position: The company ranks below industry medians across most financial metrics, particularly in profitability (ROE, margins), efficiency (working capital management), and financial health (liquidity, leverage). The primary competitive disadvantage lies in operational efficiency and capital structure. The company's strategic focus on high-growth Electronics & Innovative Products segment and chloroprene restructuring are appropriate responses, but financial performance gaps versus peers will require sustained execution to close.
※ Industry: Manufacturing sector (N=98 companies for most metrics), Comparison period: FY2025 Q3, Source: Proprietary analysis of publicly available financial data
Earnings quality and extraordinary item dependency (HIGH): Net income of ¥2.1B in Q3 and full-year guidance of ¥15.0B are heavily dependent on extraordinary items rather than recurring operations. Q3 special losses totaled ¥14.2B (primarily DPE restructuring charges ¥13.5B) partially offset by special gains of ¥8.7B (Ofuna site sale ¥8.2B). Management expects Q4 to generate ¥12.9B standalone net income through additional policy-holding stock sales offsetting further DPE extraction costs. This structure creates significant earnings volatility and guidance risk. If policy stock disposal gains cannot be realized due to market conditions, full-year net income could fall short by several billion yen. Recurring earning power remains constrained by high interest burden (¥1.6B in Q3) consuming 45-55% of operating income, structural drag that persists regardless of one-time items.
Working capital deterioration and cash conversion (HIGH): Cash Conversion Cycle has extended to 228 days (DSO 115 days, DIO 194 days), more than double the manufacturing industry median of 108 days. Inventory turnover of 194 days is nearly 2x industry median of 109 days, indicating significant excess inventory or slow-moving products. Receivables turnover of 115 days versus industry median 83 days signals collection challenges. These working capital inefficiencies consume substantial cash and suppress free cash flow generation despite improved operating income. The ¥78.7B inventory balance represents potential obsolescence risk, particularly in Elastomer segment given chloroprene demand weakness. Without meaningful CCC reduction, the company will struggle to generate organic cash flow sufficient to fund ¥57.0B annual CapEx, ¥8.6B+ dividends, and ¥1.6B+ interest payments, potentially requiring continued asset sales or debt increases. Quality alerts indicate earnings may not be converting to cash efficiently.
Financial structure and liquidity constraints (MEDIUM-HIGH): Current Ratio of 1.30x and Quick Ratio of 0.895x are substantially below manufacturing industry medians (2.84x and implied >1.0x respectively), indicating constrained short-term liquidity. Cash balance of ¥30.4B provides only 60% coverage of short-term liabilities (¥50.5B in current portion of borrowings plus other current liabilities). While the company has extended debt maturities (long-term borrowings +¥37.0B, short-term -¥23.6B), total interest-bearing debt of ¥168.1B with Debt/Capital ratio of 35.0% and Financial Leverage of 2.1x (versus industry median 1.53x) creates ongoing interest burden and refinancing risk. Interest expense of ¥1.6B in Q3 represents material drag on profitability. In a rising rate environment or if operating performance weakens, the company's ability to service debt and maintain dividend could be challenged. Equity ratio of 47.7% (versus industry median 63.8%) provides limited buffer.
Structural profitability improvement underway but sustainability uncertain: Operating income improved 54.0% to ¥18.2B with margin expansion to 6.3% from 3.9%, driven primarily by DPE restructuring effects (+¥4.2B in Q3 cumulative, +¥8.6B projected full-year). The Electronics & Innovative Products segment demonstrated sustainable growth momentum with operating income of ¥9.7B (+¥2.8B YoY) from AI-related semiconductor materials demand, representing over 50% of consolidated operating income and confirming its role as the strategic core business. This segment's 12.8% operating margin and volume-driven growth trajectory indicate competitive positioning in high-value markets. However, overall profitability remains constrained by persistent structural headwinds: interest burden consuming 45-55% of operating income, working capital inefficiencies (CCC 228 days), and business mix including loss-making Elastomer segment. ROE of 1.8% and operating margin of 6.3% both trail industry medians significantly (5.0% and 8.3% respectively), indicating sustained execution will be required to close competitive gaps. The key observable trend is bifurcation between the high-performing Electronics business and legacy chemical operations requiring continued restructuring.
Cash generation quality and capital allocation sustainability require monitoring: The absence of operating cash flow disclosure combined with severe working capital deterioration (inventory +194 days, receivables +115 days versus industry medians of 109 and 83 days) raises material concerns about cash conversion quality. High CapEx intensity (¥57.0B annual, 1.97x D&A versus industry 1.44x) reflects necessary growth investment in Electronics capacity but creates near-term free cash flow pressure. Dividend commitment of ¥100 per share (57% payout on guidance, but 160% on Q3 trailing earnings) depends critically on achieving net income guidance through Q4 extraordinary gains (policy stock sales). Current ratio of 1.30x (industry median 2.84x) and quick ratio of 0.895x indicate limited liquidity buffers. The company's ability to simultaneously fund growth CapEx, maintain dividends, and service ¥168.1B interest-bearing debt without further asset monetization or debt increases is not evident from current cash generation metrics. The observable financial characteristic is dependence on asset recycling (Ofuna sale ¥8.2B, planned policy stock sales) rather than organic free cash flow to support capital allocation.
Guidance achievement and earnings normalization pathway warrant close observation: Full-year guidance maintained at ¥25.0B operating income and ¥15.0B net income, with Q3 progress rates of 72.8% and 13.7% respectively. The dramatic gap in net income progress reflects planned Q4 extraordinary item management—additional DPE losses offset by policy stock disposal gains. This structure creates binary guidance risk contingent on successful Q4 gain realization and introduces earnings volatility that obscures underlying business trends. Recurring earning power excluding extraordinary items approximates ¥7-8B (ordinary income ¥13.7B in Q3 less normalized tax), substantially below reported net income guidance. Investors should focus on operating income trajectory and Electronics segment momentum as more reliable indicators of business performance, while recognizing that reported net income will remain volatile due to ongoing restructuring and asset sales. The completion of DPE workforce optimization (target approximately 100 personnel by April 2026) and stabilization of chloroprene operations represent key milestones for earnings normalization.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.